---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-027202"
form_type: "8-K"
ticker: "MIRA"
cik: "0001904286"
company_name: "MIRA PHARMACEUTICALS, INC."
filed_at: "2026-06-04T12:00:41+00:00"
generated_at: "2026-06-04T12:06:20.147446+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# MIRA secures worldwide exclusive rights to MIRA-55 and SKNY-1 via amended license

## Summary
- Amended license with MIRALOGX LLC grants MIRA global exclusive rights to develop, commercialize, sublicense, and enforce IP for MIRA-55 and SKNY-1.
- Core economic terms from prior license arrangements remain materially unchanged; no upfront or milestone payments disclosed.
- MIRA CEO says the company now controls worldwide rights across entire pipeline: Ketamir-2, MIRA-55, and SKNY-1.
- MIRA-55 targets chronic inflammatory pain; SKNY-1 targets obesity and addiction-related disorders—both investigational.
- Agreement consolidates IP portfolio and enhances flexibility for future licensing and partnership opportunities.

## SEC filing metadata
- accession: 0001493152-26-027202
- form_type: 8-K
- ticker: MIRA
- cik: 0001904286
- company_name: MIRA PHARMACEUTICALS, INC.
- filed_at: 2026-06-04T12:00:41+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1904286/000149315226027202/0001493152-26-027202-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1904286/000149315226027202/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-027202
- JSON: https://secwatch.observer/filing/0001493152-26-027202.json
- Plain text: https://secwatch.observer/filing/0001493152-26-027202.txt

## Key facts
- Material Agreements
  MIRA PHARMACEUTICALS, INC. amended Amended and Restated Exclusive License Agreement with MIRALOGX LLC (effective 2026-06-03).
  - Action: amendment
  - Agreement: license
  - Counterparty: MIRALOGX LLC
  - Effective: 2026-06-03
  source text: On June 3, 2026, MIRA Pharmaceuticals, Inc. (the "Company") entered into an Amended and Restated Exclusive License Agreement (the "License Agreement") with MIRALOGX LLC ("Miralogx").
  evidence_url: https://www.sec.gov/Archives/edgar/data/1904286/000149315226027202/0001493152-26-027202-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.